Authors: Stephen Gottschalk, St. Jude Children’s Research Hospital (TN, USA)
In this interview with Stephen Gottschalk from St. Jude Children’s Research Hospital (TN, USA) discover some of the challenges in developing CAR-T therapies for solid tumors, major milestones in their development and where the field is heading.
Could you give us a brief outline of the talk you recently presented at AACR 2018?
I presented at American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA) in a session titled “Scientific and Regulatory Challenges in Development of CAR-T Therapy for Solid Tumors,” which was organized by Ke Liu from the US FDA. Carl June presented data from his clinical studies targeting mesothelin with CAR-T cells for pancreatic cancer, and Behnam Badie presented the results of clinical studies using IL13Ra2-specific CAR-T cells for high-grade glioma. Gary Archer focused on the evaluation of CAR-T cells in preclinical glioma models and I described the outcome of our clinical studies with HER2-CAR-T cells for sarcoma and high-grade glioma. At the end, Peter Boss reviewed the current status of CAR INDs and CAR protocols from an FDA perspective.